Quest Diagnostics AAVrh74 Antibody ELISA CDx
Quest Diagnostics Nichols Institute · Decision date Jul 24, 2025
What did the FDA approve?
FDA records P250002 as an original PMA application. The recorded decision is approval, dated Jul 24, 2025.
FDA approval order statement
Quest Diagnostics AAVrh74 Antibody ELISA CDx is an enzyme-linked immunosorbent in vitro diagnostic assay intended for the semi-quantitative detection of antibodies (IgG) to AAVrh74 capsid in human serum. The test reports an antibody titer, and a semi-quantitative interpretation of the test results derived from the antibody titer. Patients with an AAVrh74 antibody titer less than 1:400 are reported as not elevated for AAVrh74 antibody titers and may be eligible for treatment with the gene therapy. Patients with an AAVrh74 antibody titer greater than or equal to 1:400 are reported as elevated for AAVrh74 antibody titers and are ineligible for treatment with the gene therapy. The test is for prescription use only. The test is intended to be used in conjunction with other available clinical information as an aid to identify patients eligible for treatment with indicated gene therapies.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Hematology
- Decision date
- Jul 24, 2025
Regulatory record facts
- Identifier
- P250002
- Regulatory pathway
- Premarket approval application
- Applicant
- Quest Diagnostics Nichols Institute
- Product code
- QWQ
- Decision code
- APPR
- Decision date
- Jul 24, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Assays to detect pre-existing antibodies to adeno-associated virus (AAV) viral vectors.
- Applicant
- Quest Diagnostics Nichols Institute
- Product code
- QWQ
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P250002 received
Application receipt date recorded by FDA.
P250002 · FDA decision
APPR
Timeline entries are records held by MedtechLedger for P250002. View FDA’s full supplement list.
Related devices and submissions
Explore the linked device profile
No additional submissions with a verified PMA or product-code relationship are linked here.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Quest Diagnostics Nichols Institute
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 33608 Ortega Hwy., San Juan Capistrano, CA, 92675
Sources and methodology
- Original FDA record: P250002
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records